Lymphoma (cHL) immunotherapy! Mercadon Keytruda (Korida) Head-to-head Phase III trial efficacy beat swata Adcetris (Ansili)!

19 May 2020 /PRNewswireBIOON/-Merck and Co recently announced the results of the anti-PD-1 therapy Keytruda (Creeda, generic name: Pembrolizumab, Pablo Bezumab) treatment of classic Hodgkin's lymphoma (cHL) head-to-head key phase III KEYNOTE-204 trial (NCT2684292)The data showed that in adult patients with recurrent or refractory (r/r) cHL, Keytruda significantly increased the risk of disease progression or death by 35% and non-progressive survival (PFS) significantly (median PFS: 13.2 months vs8.3 months) compared to the standard care drug Adcetris (brentuximabvedotin)Adcetris (Chinese: Ambtous, Injectable Vibutusiprosy) is an antibody-targeted CD30 antibody drug conjugate (ADC) developed by Takeda Pharmaceuticals and SeattleGenetics, and is the standard nursing drug for the treatment of recurrent or refractory Hodgkin's lymphoma (r/rcHL)In China, Adcetris (Adcetris) was recently approved by the State Drug Administration for treatment of adult patients with recurrent or refractory systemic degenerative large cell lymphoma (sALCL) or CD30-positive Hodgkin lymphoma (HL)(See:redefinely treatment for lymphoma!) Takeda Antibody Drug Coupling (ADC) Adcetris (Asili, Vibutusixim) has been officially approved by China!)it is worth mentioning thatKEYNOTE-204 is the first Phase III trial to evaluate positive results for an anti-PD-1 therapy r/rcHLMarch 2017, U.SThe FDAexpedite the approval of Keytruda for the treatment of patients with refractory cHL adults and children, or cHL patients who have previously received three or three relapses after the programThis accelerated approval is based on tumor remission and remission persistence data based on phase II KEYNOTE-087 trials Phase III KEYNOTE-204 trial is a validation test of keytruda in cHL therapeutic indications Mercado plans to submit the data to global regulators this year Dr Jonathan Cheng, associate director of oncology clinical research at the 's Mercadon Research Laboratory, said: "In this head-to-head study, Keytruda has improved statistically and clinically significantly in progressionless survival compared to Brentuximabvedotin, which enhances Keytruda's advantage in classic Hodgkin's lymphoma Through a wide range of clinical projects to evaluate Keytruda's to treat malignant tumors in a variety of blood systems, Mersadon is dedicated to researching innovative approaches to the treatment of blood cancer Dr John Kuruvilla, a haematologist and associate professor of medicine at the Princess Margaret Cancer Center at the University of Toronto, Canada, said: "These data are particularly significant because about 15 to 20 percent of patients with cHL (the most common type of Hodgkin's lymphoma) are not usually relieved after first-line treatment Data from the KEYNOTE-204 trial show that Keytruda monotherapy has the potential to change the current treatment patterns of cHL patients, who are generally young and whose prognosis will be poor if they do not achieve remission Classic Hodgkin's Lymphoma (cHL, photo source: atlasgeneticsoncology.org) KEYNOTE-204 is a randomized, open-label, head-to-head Phase III trial that assessed the efficacy and safety of Keytruda monodotherapy and BV treatment r/rcHL The trial included a total of 304 adult patients aged 18 years, randomly assigned to Keytruda (200mg intravenous infusion, the first day of each cycle, every 3 weeks for a cycle, treatment 35 cycles) or BV (1.8 mg/kg) (maximum dose 180 mg), the first day of each cycle, one cycle per 3 weeks, treatment 35 cycles The common primary endpoints of the experiment were Progressless Lifetime (PFS) and Total Lifetime (OS), and key secondary endpoints included objective mitigation rates (ORR), full mitigation rates (CR), and safety results show that the study reached one of the two main endpoints of the progression-free survival (PFS) According to a mid-term analysis conducted by the Independent Data Monitoring Committee (DMC), the Keytruda treatment group achieved a statistically significant and clinically significant improvement in PFS compared to the BV treatment group in this patient group specific data were: Compared to the BV group, the risk of disease progression or death in the Keytruda group was significantly reduced by 35% (HR s.65 (95% CI: 0.48-0.88), p.00271), PFS significantly extended (median PFS: 13.2 months vs8.3 months), and one year progression survival rate increased (53.9%) vs 6.6% In addition, the OrR in the Keytruda group was 65.6%, the BV group was 35.6%, the keytruda group had a partial mitigation rate (PR) of 41.1% and the BV group was 30.1% The bit-in-the-bit mitigation duration (DOR) in the Keytruda group was 20.7 months (range: 0.0 to 33.2 plus) and in the BV group 13.8% (range: 0.0 plus to 33.9 plus) , according to a pre-specified analysis plan, there is no formal inspection of another common primary endpoint OS in this interim analysis The study will continue to evaluate OS safety, the incidence of treatment-related adverse events (TRAE) was similar in the Keytruda group (74.3%) and the BV group (77.0%) 3-5 rate of TRAE incidence, Keytruda group (19.6%) lower than BV group (25.0%) A treatment-related death (pneumonia) occurred in the Keytruda group Keytruda is a PD-(L)1 tumor immunotherapy that helps detect and fight tumor cells by improving the body's immune system Keytruda is a human-derived monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, activating T lymphocytes that may affect tumor cells and healthy cells To date, 11 PD-1 oncology immunotherapy have been approved worldwide, with Keytruda as the leader in the field, with more than 20 treatments approved and global sales reaching $11.1 billion in 2019 , Mersadon is continuing to study Keytruda's treatment of malignancies in a variety of blood systems, including three registered trials of cHL and primary isolated large B-cell lymphoma (PMBCL), and more than 60 studies initiated by researchers covering 15 types of tumors In addition to Keytruda, Mercadon is evaluating an oral Bruton tyrosine kinase (BTK) inhibitor MK-1026 (formerly known as ARQ531), which the company acquired after its recent lying $2.7 billion acquisition of ArQule At present, MK-1026 is in the treatment of B cell malignant tumor phase II dose expansion study with the largest clinical development of immuno-oncology in the industry, Mersadon, there are more than 1,000 clinical trials investigating Keytruda's role in multiple types of tumor and treatment background The Keytruda Clinical Project aims to understand the role of the drug in cancer and the factors that may predict patients will benefit from Keytruda treatment, including exploring several different biomarker (biovalleybioon.com) original source: Merck's SuperiorsKEYTRUDA (pembrolizumab) Brentuxima b Vedotin (BV), a StandardofCare, inPatientsWith Classical Hodgkin Lymphoma (cHL) in Head-to-HeadPhase3Trial